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Abstract
Background: RNA interference (RNAi) is a conserved gene silencing mechanism mediated by small inhibitory
microRNAs (miRNAs).
Promoter-driven miRNA expression vectors have emerged as important tools for delivering natural or artificially
designed miRNAs to eukaryotic cells and organisms. Such systems can be used to query the normal or pathogenic
functions of natural miRNAs or messenger RNAs, or to therapeutically silence disease genes.
Results: As with any molecular cloning procedure, building miRNA-based expression constructs requires a time
investment and some molecular biology skills. To improve efficiency and accelerate the construction process, we
developed a method to rapidly generate miRNA expression vectors using recombinases instead of more traditional
cut-and-paste molecular cloning techniques. In addition to streamlining the construction process, our cloning
strategy provides vectors with added versatility. In our system, miRNAs can be constitutively expressed from the U6
promoter, or inducibly expressed by Cre recombinase. We also engineered a built-in mechanism to destroy the
vector with Flp recombinase, if desired. Finally, to further simplify the construction process, we developed a
software package that automates the prediction and design of optimal miRNA sequences using our system.
Conclusions: We designed and tested a modular system to rapidly clone miRNA expression cassettes. Our strategy
reduces the hands-on time required to successfully generate effective constructs, and can be implemented in labs
with minimal molecular cloning expertise. This versatile system provides options that permit constitutive or
inducible miRNA expression, depending upon the needs of the end user. As such, it has utility for basic or
translational applications.
Background
The central dogma of molecular biology describes how
the genetic information encoded in DNA is used to
make proteins. Although RNAs were long known to
play crucial roles in this process (e.g. mRNAs, tRNAs,
rRNAs), their importance in gene expression control has
dramatically expanded with the recent discovery of RNA
interference (RNAi) [1,2]. In the simplest terms, RNAi
refers to sequence-specific gene silencing occurring after
mRNA transcription, and the principal regulators of this
process are small, non-coding microRNAs (miRNAs)
[3,4].
Natural miRNAs are encoded in the genomes of
eukaryotes and some viruses [2-7]. Over 1,000 miRNAs
were identified in recent years, and the major steps and
players involved in miRNA biogenesis have been largely
defined [8-24]. This knowledge provided the foundation
for developing expression systems to deliver engineered
inhibitory RNAs, like shRNAs and artificial miRNAs, to
various cells and tissues in vitro and in vivo [9,25-28]. In
essence, these vectors operate as siRNA or mature
miRNA delivery vehicles; as there is not universal
nomenclature for such systems, we note that they are
referred to as “artificial miRNA shuttles” in this manu-
script. Importantly, these artificial miRNA shuttles can
be engineered to knockdown any gene of interest
[9,25,26,28,29]. As a result, they have emerged as power-
ful molecular tools for querying natural miRNA
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genomics studies, or developing RNAi-based therapies
for disease [30]. Indeed, several pre-clinical studies sup-
port that RNAi-based therapies are promising
approaches for treating dominant genetic diseases, viral
pathogens, and cancer [30-40].
Our laboratory is interested in developing RNAi thera-
pies for dominantly inherited disorders [34,40]. This
work requires delivering artificial therapeutic miRNA
shuttles to target cells and tissues. Numerous groups,
including ours, have described various expression vectors
in recent years [25-28,32,33,36,41-51]. The most com-
monly used systems rely upon constitutively active pro-
moters, such as U6, to drive inhibitory RNA
transcription. These vectors are typically constructed
using traditional cut-and-paste molecular cloning techni-
ques, and multiple constructs are often required to iden-
tify ones capable of effectively silencing target genes [29].
To streamline the construction process and make it less
labor-intensive, we developed a procedure to rapidly gen-
erate artificial miRNA expression vectors using a com-
mercially available phage recombinase system (Gateway
®
Technology from Invitrogen™). In so doing, we also cre-
ated a method that provides tightly controlled, inducible
miRNA expression, and a built-in mechanism to destroy
the vector, if desired. We named our method the Gate-
way
®-Ready Inducible MiRNA (GRIM) expression sys-
tem (Figure 1). In this manuscript, we describe a detailed
protocol for GRIM vector construction and demonstrate
the functionality of our system in mammalian cells.
Methods
GRIM Destination Vector construction
The GRIM destination vector was constructed by
recombinant PCR from two products. The first product
contained the mouse U6 promoter flanked by single
FRT and LOXP sites at the 5’ and 3’ ends, respectively.
In addition, 18 nucleotides corresponding to the 5’ por-
tion of the AttP1 site were added downstream of LOXP
(product A). Product A primers were: 577 Forward (5’
TTCAATTGTAGACTAGTGAAGTTCCTATTCTCTA-
GAAAG 3’) and 685 Reverse (5’ GGGGCCCGAGCT-
TAAGACATAACTTCGTAT AGCATACATTATAC
3’). The second product (Product B) was the Gateway
®
Cassette, containing the ccdB and chloramphenicol
resistance (CmR) genes flanked by AttP1 and AttP2
sites, which was amplified from pDONR221. This cas-
sette was also engineered to contain 25 nucleotides of a
LoxP site at the 5’ end. Product B primers were: 684
Forward (5’ GTATAATGTATGCTATACGAAGT-
TATGTCTTAAGCTCGGGCCCC 3’) and 578 Reverse
(5’ AACAATTGGTAACATCAGAGATTTTGAGACAC
3’). Products A and B were then stitched together by 10
cycles of recombinant PCR using the overlapping LoxP
and AttP1 sequences, followed by 30 cycles of exponen-
tial amplification using primers 577 and 578. The resul-
tant 2,922 bp PCR product was gel purified, cloned into
pCR
®-Blunt II-TOPO (Invitrogen), transformed into
One Shot
® ccdB Survival™ competent cells (Invitrogen),
and plated onto LB agar plates containing chloramphe-
nicol. Minipreps from restriction positive colonies were
sequenced to confirm accuracy.
Linear miRNA Donor construction
The 219 bp linear miRNA donor sequences were con-
structed from 4 primers, two of which are common to all
constructs, and two that are unique to the cloned miRNA
sequences. This strategy is described in the Results section
and primer sequences detailed in Additional File 1. For this
study, we built GRIM vectors containing two different
microRNA sequences (miLacZ and miGFP) targeting LacZ
and eGFP reporters, respectively (Additional File 1). For
miRNA donor construction, one microgram of each primer
was mixed together in a 50 microliter reaction with Pfx
polymerase (Invitrogen) and thermocycled using the fol-
lowing conditions: 95°C × 30 sec, 45°× 30 sec, and 68°C ×
30 sec for 35 cycles. Full-length miRNA donor bands were
visualized on ethidium bromide stained agarose/TBE gels
(Additional File 2) to ensure primer extension. However,
we found that gel or column purification was unnecessary
for BP cloning into the GRIM destination vector.
BP recombination reaction and clone verification
Three microliters of the 50-microliter miRNA donor
reaction was combined with 150 ng of the Gateway
®
Destination vector, and this DNA mixture was then
added to a 10 microliter, room temperature BP Clonase
reaction (Invitrogen) for 1 hour using manufacturer’s
instructions. BP Clonase was inactivated with Proteinase
K, following manufacturer’s instructions, and 2 microli-
ters of the BP reaction was transformed into chemically
competent, ccdB sensitive TOP10 E. coli cells (Invitro-
gen). Colonies were selected on LB agar plates contain-
ing kanamycin. Resistant colonies were DNA
miniprepped (Qiagen Spin miniprep kit) and digested
with EcoRI (New England Biolabs), and electrophoresed
on a 1% agarose/TBE/ethidium bromide gel to deter-
mine clone correctness (Additional File 2). Correctly
recombined clones (GRIM.miRNA
off)s h o wt w oE c o R I
bands of 3,501 and 900 bp, while the empty GRIM des-
tination vector has three EcoRI fragments of 3,501,
2,170, and 805 bp (Additional File 2). BP recombination
had a 90% efficiency for both the miLacZ and miGFP
constructs. Restriction positive colonies were DNA
sequenced (Big Dye
® Terminator Cycle Sequencing Kit,
Applied Biosystems) using a primer located at the 3’
end of the U6 promoter (5’ CACAAAAGGA AACT-
CACCC 3’).
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on vectors in E. coli
GRIM.miRNA
off vectors can be permanently switched on
by transformation into EL350 E. coli cells, which express
Cre recombinase from the arabinose-inducible promoter
[52]. Cre recombinase was induced by L-(+)-Arabinose
prior to making cells electrocompetent. Cre
+ EL350 cells
were then transformed with 1 ng GRIM.miRNA
off plas-
mid, and grown overnight at 32°C on LB agar plates con-
taining kanamycin. Resistant colonies were seeded into
miniprep cultures, and agitated overnight in LB/kanamy-
cin liquid media at 32°C. Following DNA miniprep,
FLOXed clones were identified by EcoRI digestion and
electrophoresis. Positive GRIM.miRNA
on colonies show
two EcoRI bands at 3,501 and 725 bp, compared to 3,501
and 900 bp from unFLOXed GRIM.miRNA
off vectors
(Additional File 3). In our experiments, Cre excision was
100% efficient in EL350 cells.
Transient gene silencing studies
GRIM.miGFP
HEK293 cells were co-transfected (Lipofectamine-2000,
Invitrogen) with 25 ng of a CMV.eGFP expression vec-
tor (pVETLeGFP)[41] and 775 ng indicated miRNA
expression plasmid (Figure 2) in duplicate on 24 well
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Figure 1 Overview of GRIM system. Details are described in the Results and Methods sections. (A) GRIM.miRNA vectors are constructed by BP
recombination between a linear miRNA donor and our GRIM destination vector. Each linear miRNA donor is created by extending 4 DNA
primers. Common primers 1 and 2 are used to build every linear miRNA donor DNA, and contain identical AttB, LoxP, and FRT sequences, as
shown. The middle portion of the linear miRNA donor is generated by DNA oligos containing miRNA sequences designed by the end-user or
using our GRIM.REAPER software package (Additional File 4). BP recombination produces the GRIM.miRNA
off vector, which contains a LoxP-
flanked 5’ AttL1 site that inhibits miRNA production. The AttL1 site can be removed by Cre recombinase to produce the constitutively active
GRIM.miRNA
on vector. The entire U6 promoter (U6 prom) miRNA cassette is flanked by FRT sites, which can be utilized to shut down the system
in the presence of Flp recombinase. (B) Predicted secondary structure of the LoxP-flanked AttL1 site, which inhibits miRNA production. Cre
excision of AttL1 releases this inhibition, thereby permitting miRNA expression. The miLacZ sequence is shown here (blue indicates sense strand;
red indicates antisense guide strand). Nucleotides in orange are stem and loop sequences derived from human miR-30a, except the 3’ terminal
poly U, which is an engineered termination signal for the pol III-dependent U6 promoter. The blue and yellow arrowheads indicate Drosha and
Dicer cut sites, respectively.
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Page 3 of 10plates. GFP epifluorescence was imaged using a fluores-
cent inverted microscope equipped with a digital camera
24 hours later.
GRIM.miLacZ. HEK293 cells were co-transfected with 20
ng CMV.bgal expression plasmid and 180 ng of the indi-
cated miRNA expression constructs (Figure 2) in triplicate
on 96 well plates with white walls and clear bottoms. The
next day, cells were lysed for 10 minutes using 10 microli-
ters of Galacto-Light™ kit lysis buffer (Applied Biosystems).
One microliter of lysate was used to quantify total protein
by Lowry assay (BioRad DC™ Protein Assay). b-galactosi-
dase activity was then measured from the remaining 9
microliters of lysate following manufacturer’s instructions.
Triplicate data were averaged per condition, and three inde-
pendent experiments performed. b-galactosidase activity
was normalized to Lowry assay-determined protein content.
GRIM.miLacZ with Flp/FRT system
HEK293 cells were co-transfected with 10 ng CMV.bgal
and indicated plasmids (Figure 3B). Where indicated,
cells received 30 ng CMV.Cre, 130 ng GRIM.miLacZoff,
and/or 30 ng CMV.Flp recombinase. bgal activity was
measured as described above. All wells received equiva-
lent molar amounts of plasmid, such that an empty U6
plasmid was used to normalize DNA loading in transfec-
tion liposomes, when necessary.
Northern blot
Four micrograms of indicated GRIM.miLacZ and control
plasmids were transfected into HEK293 cells on 6 well
plates. One day later, total RNA was extracted using the
miRVANA kit (Ambion). Five micrograms of total RNA
per well was loaded on an urea/polyacrylamide/TBE gel,
along with DNA oligonucleotides containing antisense (+)
or sense (-) miLacZ sequences, as previously described
[33]. The gel was run at 20 mA until bromophenol blue
dye reached the bottom, then separated RNAs were trans-
ferred to Nylon membranes (Nytran N+) at 200 mA for
45 minutes in 0.5× TBE. Membranes were then cross-
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Figure 2 GRIM.miRNA
off vectors are turned ‘on’ by Cre
recombinase. (A) GFP epifluorescence in HEK293 cells
demonstrates GRIM.miGFP
on functionality. Cells were transfected 24
hours prior with CMV.eGFP and indicated miRNA expression
plasmids. GFP knockdown was evident in cells transfected with the
traditionally cloned U6.miGFP plasmid or its GRIM.miGFP
on
counterpart, compared to cells containing an empty U6 promoter
(U6 control). In contrast, GRIM.miGFP
off did not cause GFP gene
silencing. Images shown are representative of three independent
experiments. (B) bgal assay confirms the Cre-inducibility of the GRIM
system. HEK293 cells were transfected with CMV.LacZ and indicated
miRNA or control expression plasmids. Only the traditionally cloned
U6.miLacZ and the GRIM.miLacZ
on analog caused statistically
significant LacZ gene silencing (ANOVA, p < 0.05). All other
constructs had no impact on bgal activity. Error bars indicate
standard error of the mean (s.e.m.). U6T6 is an empty U6 promoter
plasmid. UNT, untransfected HEK293 cells. (C) Small transcript
northern blot shows that Cre induces full-length and processed
GRIM.miLacZ. In contrast, GRIM.miLacZ
off vectors do not express full-
length or processed miRNAs. +, indicates a positive control DNA
oligo containing the miLacZ antisense sequences. -, indicates
negative DNA control corresponding to the miLacZ sense strand. A
radiolabeled version of this oligo was also used to probe the blot.
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Page 4 of 10linked and hybridized with a
32P end-labelled DNA oligo
(5’-End Labelling Kit, GE Healthcare) that detected the
antisense guide strand of the miLacZ sequence, in Oligo
Hyb Buffer (Ambion) for two days at 36°C. The membrane
was then washed three times at room temperature and
twice at 36°C in 2× SSC, exposed to autoradiographic film
(Amersham Hyperfilm™, GE Healthcare) at -80°C, and
developed 7 days later.
Generation of Stable HEK293 cells
HEK293 cells were transfected (Lipofectamine-2000,
Invitrogen) with a 1:3 molar ratio of CMV.bgal and
PGK.Neo plasmids in a 60 mm plate. Two days later,
400 μg/ml G418 was added to tissue culture media
(DMEM with 10% FBS, 1% penicillin/streptomycin, 1%
L-glutamine) and cells were passaged and selected for 4
weeks. G418 resistant cells were then plated at low den-
sity, 24 different single colonies were picked and
expanded, and representative cells from each colony
were stained for b-gal activity (b-gal Staining Kit, Invi-
trogen) using manufacturer’si n s t r u c t i o n s .S i xo f2 4
colonies were bgal positive, and we ultimately selected a
line that had consistent bgal expression in all cells. This
line was then co-transfected (Lipofectamine-2000) in a
12-well plate with 1280 ng GRIM.miLacZ
off and 320 ng
of a CAG.Puromycin Resistance (PuroR) plasmid. Two
days later, we began selection in Puromycin (1 μg/ml
concentration in media) for one month, and then PCR
screened resistant cells for GRIM.miLacZ
off presence.
Validation of the Flp/FRT System in Stable HEK293/bgal
cells
Puro
R/G418
R stable HEK293/bgal/GRIM.miLacZ
off cells
were transiently transfected with a CMV.Cre expression
plasmid (Lipofectamine-2000, Invitrogen), and bgal
activity was determined in the parent and FLOXed
stable cells 5 days later, to ensure GRIM.miLacZ-
mediated bgal knockdown. Four weeks later, FLOXed
GRIM.miLacZ
on cells were transfected with the pOG44
CMV.Flp expression plasmid (Stratagene). bgal activity
was then measured 5 days later using the Galacto-
Light™ kit lysis buffer (Applied Biosystems), as
described above. Data are representative of 3 indepen-
dent experiments.
Results
Construction of GRIM vectors: Overview
A n yi n h i b i t o r yR N As e q u e n c ec a nb ec l o n e di n t ot h e
GRIM vector system using our universal strategy. A
general overview of this method is shown in Figure 1
and the detailed protocol is described in Additional Files
1,2 and 3. The initial cloning reaction requires three
major components: the GRIM destination vector, a lin-
ear miRNA donor, and BP Clonase™ enzyme, derived
from lambda phage recombinases (Invitrogen™).
The GRIM destination vector contains the RNA poly-
merase III-dependent mouse U6 promoter cloned
upstream of a Gateway
® selection cassette. Single FRT
and LoxP sites, which are substrates for Flp and Cre
recombinases, respectively, flank the U6 promoter at its
5’ and 3’ ends (Figure 1A).
In our system, the linear miRNA donor is based on
sequences and structures derived from human miR-30a
(Additional File 1) [9,17,28]. We build the miRNA
donor by annealing 4 DNA primers and filling in gaps
with a thermostable DNA polymerase, such as Taq or
Pfx. The two outside primers (Figure 1A; common pri-
mers 1 and 2) are universal for building all linear
KanR
FRT
SITE
LOX
P
Att
L2
MiRNA U6 Prom FRT
SITE
GRIM.miRNAon vector A
KanR
FRT
SITE
Att
L2
Destroyed vector
+ Flp Recombinase
B
0.0
0.2
0.4
0.6
0.8
1.0
1.2
HEK293
Stables
CRE FLP
R
e
l
.
 
B
g
a
l
 
A
c
t
i
v
i
t
y
HEK293
Stables
CMV.Bgal ON
GRIM.miLacZ OFF
Transfect
CMV.CRE
5 days - 4 wks
5 days
Transfect
CMV.FLP
CMV.Bgal ON
GRIM.miLacZ ON
CMV.Bgal ON
GRIM.miLacZ OFF
Figure 3 GRIM.miRNA
on vectors are turned ‘off’ by Flp recombinase. (A) GRIM.miRNA
on vectors contain FRT sites flanking the U6.miRNA
sequences. The entire U6.miRNA expression cassette can therefore be removed with Flp recombinase, thereby permanently switching the vector
‘off’. (B and C) Testing the Flp off-switch. We generated a line of HEK293 cells stably expressing a CMV.bgal the GRIM.miLacZ
off plasmids
(described in Methods). Transient transfection of CMV.Cre significantly reduced bgal activity in these cells, and this silencing was maintained for
up to 4 weeks (our longest timepoint) compared to the parent, unFLOXed cells (ANOVA, p < 0.05). bgal activity was significantly increased 5
days after transiently transfecting GRIM.miLacZ
on stable cells with the pOG44 CMV.Flp expression plasmid (ANOVA, p < 0.05), which encodes a
Flp protein isoform with suboptimal activity at 37°C. Error bars indicate s.e.m.
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Page 5 of 10miRNA donors, while the two internal ones (miRNA
primers 1 and 2) provide the unique miRNA sequences
designed by the end user (Figure 1A and Additional File
1). Common primer 1 contains a terminal AttB1 site fol-
lowed by a LoxP site and 15 nucleotides derived from
the lower stem of human miR-30a (Figure 1 and Addi-
tional File 1). Common primer 2 is a minus strand oli-
gonucleotide encoding a terminal AttB2 site, an optional
FRT site, 13 nucleotides of the human miR-30a lower
stem, and a RNA polymerase III termination signal
(TTTTTT). In addition to encoding the unique miRNA
sense and antisense sequences, the internal miRNA pri-
mers 1 and 2 also contain human miR-30a stem and
loop sequences, which provide common complementary
regions for primer annealing. The primer design and
annealing strategy is detailed in Additional File 1. In
addition, we developed a software package that auto-
mates the GRIM.miRNA shuttle prediction and design
process (Additional File 4).
Extending the two common and two miRNA-specific
primers produces a full-length 219 bp linear miRNA
donor DNA (Additional Files 1 and 2), which is then
used in a BP recombination reaction with the GRIM
destination vector (Figure 1). Smaller, incompletely
extended products are also generated but lack full-
length AttB sites and are therefore incapable of partici-
pating in the BP reaction (Additional File 2). As a result,
gel purification of the full-length linear miRNA donor
DNA is unnecessary (discussed in greater detail in sup-
plementary materials; Additional Files 1, 2 and 3).
The parent GRIM destination vector is kanamycin
resistant (KanR) and contains an active ccdB (control of
cell death B) gene in the Gateway
® cassette region.
CcdB gene expression is lethal to most transformation-
competent E. coli used in laboratories for molecular
cloning purposes. BP recombination replaces the ccdB-
containing Gateway
® cassette with the linear miRNA
donor DNA. This reaction also converts AttB and AttP
sites to a 118 bp hybrid sequence called AttL (Figure 1).
Thus, ccdB-sensitive cells will only grow when trans-
formed with properly recombined plasmids, which we
termed GRIM.miRNA
off vectors.
GRIM.miRNA
off plasmids have KanR and contain a
LoxP-flanked AttL1 site located between the mouse U6
promoter and the artificial miRNA shuttle sequence
(Figure 1B). This entire cassette is enclosed at both ends
by FRT sites. The AttL1 site inhibits miRNA produc-
tion, thereby conferring inducibility to the system.
Mature, functional miRNAs are therefore only produced
after the AttL1 site is excised (a.k.a. FLOXed) by Cre
recombinase, yielding GRIM.miRNA
on vectors (Figure
1B, Additional File 3). Alternatively, to rapidly generate
un-inducible miRNA vectors, GRIM.miRNA
off vectors
can be transformed into EL350 E. coli, which express
arabinose-inducible Cre recombinase (Additional File 3).
Finally, the flanking FRT sites permit irreversible GRIM.
miRNA
on shutdown in the presence of Flp recombinase
(Figure 1A).
GRIM.miRNA
off vectors are turned ‘on’ by Cre
recombinase
To demonstrate the functionality of our system, we
developed two different miRNA donors targeting the E.
coli LacZ and A. victoria enhanced GFP (eGFP) genes,
respectively (Additional File 1, Figure 2). We called
these sequences GRIM.miLacZ and GRIM.miGFP. We
first tested the gene-silencing efficacy of each construct
relative to a comparable U6.miRNA vector prepared
using conventional cut-and-paste cloning techniques
(U6.miGFP and U6.miLacZ). To do this, we co-trans-
fected HEK293 cells with a CMV.eGFP expression plas-
mid and U6.miGFP, an empty U6 vector, GRIM.
miGFP
off,o rG R I M . m i G F P
on constructs. Fluorescent
microscopic imaging 24 hours later revealed distinctly
less GFP expression in cells transfected with the U6.
miGFP and GRIM.miGFP
on vectors compared to the
empty U6 control. In contrast, GFP levels were compar-
ably higher and more widespread in cells expressing the
GRIM.miGFP
off plasmid (Figure 2A).
To better quantify gene silencing and confirm that the
functionality of our system was not restricted to the
miGFP sequence alone, we performed a second gene
silencing experiment using LacZ-directed miRNAs
(miLacZ) and a b-galactosidase (b-gal) reporter assay.
Specifically, we transiently co-transfected HEK293 cells
with a CMV.LacZ plasmid and conventional U6 or
GRIM-driven miLacZ and control expression vectors
(Figure 2B). One day later, we determined miLacZ-
directed gene silencing by measuring b-gal activity in
transfected cells. We found that cells expressing U6.
miLacZ and its GRIM.miLacZ
on counterpart had a sta-
tistically significant 60% reduction in b-gal activity com-
pared to all other controls (Figure 2B). In contrast, the
GRIM.miLacZ
off plasmid had no impact on b-gal levels
(Figure 2B).
Our gene silencing results using both GFP and LacZ
reporter assays suggested that the unFLOXed GRIM.
miLacZ
off vectors were incapable of producing mature,
functional miLacZ sequences. To determine this, we
performed small transcript northern blots using RNA
isolated from HEK293 cells transfected with empty U6
vector, U6.miLacZ, and the FLOXed and unFLOXed
GRIM.miLacZ constructs. The original U6.miRNA cas-
settes and their GRIM.miRNA
on counterparts are identi-
cal sequences except the GRIM vectors contain a single
LoxP at the 5’ end of the miRNA shuttle transcript, and
a r et h e r e f o r e3 4n tl o n g e r( F i g u r e1 B ) .U s i n gar a d i o l a -
beled probe targeting the miLacZ antisense strand, we
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Page 6 of 10detected identical pre-miLacZ and mature miLacZ spe-
cies in U6.miLacZ and GRIM.miLacZ
on samples, but not
in the empty U6 control or, importantly, the GRIM.
miLacZ
off lanes (Figure 2C and Additional File 1). More-
over, the GRIM.miLacZ
on sample had an additional, lar-
ger band that migrated at the expected location of the
LoxP-containing primary GRIM transcript (Figure 1B
and Figure 2C). These results demonstrated that GRIM
vectors are tightly regulated by Cre recombinase.
GRIM.miRNA vectors can be turned ‘off’ by Flp
recombinase
In some cases, it may be desirable to shutdown miRNA
expression. For example, over-expressed inhibitory RNAs
can sometimes cause unintended, non-specific off-target
effects that could be detrimental to the host cell
[33,53-55]. Alternatively, strategies for querying normal
miRNA function could include measuring specific out-
comes in miRNA-expressing cells and then determining
how these outcomes change when the miRNA is turned
off. We therefore built a mechanism into the GRIM sys-
tem to permanently remove the FRT-flanked miRNA
expression cassette with Flp recombinase (Figure 3).
We hypothesized that the optimal method to demon-
strate off-switch functionality was to reverse, rather than
prevent, GRIM.miLacZ-mediated bgal gene silencing.
This strategy required turning ‘on’ the GRIM.miLacZ
off
vector and allowing sufficient time for bgal reduction
before shutting down the system with Flp. We hypothe-
sized that this could not be accomplished in the 2-3 day
time window provided by a transient transfection
experiment. We therefore generated stable HEK293 cell
lines expressing G418-selected CMV.LacZ and Puromy-
cin-selected GRIM.miLacZ
off plasmids. After selection,
we transfected HEK293 stables with CMV.Cre, cultured
cells for several weeks, transfected again with CMV.Flp,
and then harvested cells for bgal assays. As expected
Cre-treated cells (GRIM.miLacZ
on) had significantly
reduced bgal activity compared to HEK293 stables
expressing GRIM.miLacZ
off. Importantly, transient Flp
recombinase expression significantly reversed GRIM.
miLacZ
on gene silencing (Figure 3B). These results con-
firmed that the GRIM system could be inactivated by
Flp recombinase.
Discussion
Numerous inhibitory RNA expression vectors have been
described in recent years [25,26,28,29,36,42-51]. First-
generation vector systems typically relied upon constitu-
tively active, RNA polymerase III-dependent (pol III)
promoters, such as H1 or U6, to drive uncontrolled
inhibitory RNA expression [25,29,32]. As the applicabil-
ity of RNAi as a technology became more apparent,
additional expression strategies emerged, including
embedding miRNAs into introns or 3’ UTRs of trans-
lated genes, and using constitutively active or tissue-spe-
cific RNA polymerase II-dependent (pol II) promoters
to direct transcription [36,41]. To achieve even greater
control of inhibitory RNA expression, several groups
developed doxycycline- or Cre recombinase-inducible
shRNA/miRNA systems [42-49]. These inducible vectors
have proven useful for studying normal miRNA func-
tion, functional genomics, and may also have potential
therapeutic applications, by providing fail-safe mechan-
isms to shut down inhibitory RNA expression if unin-
tended off-target effects arise.
Despite the diversity of expression strategies currently
available, virtually all share the common feature that
construction requires cut-and-paste molecular techni-
ques, which can be tedious and time-consuming. In
addition, developing optimal artificial inhibitory RNAs,
such as for therapeutic purposes, often requires building
and screening numerous constructs, which adds to the
hands-on time needed to ultimately identify the best
sequences [29]. Thus, our initial goal for engineering the
GRIM system was to simply streamline the construction
process by using a procedure dependent upon recombi-
nases instead of restriction enzymes and DNA ligase.
We decided to use the Gateway system because it was a
proven method, and the enzyme cocktail required to
implement the strategy was commercially available (BP
Clonase by Invitrogen).
As shown in Figure 1, our GRIM strategy incorporates
AttB sites onto the 5’ and 3’ ends of a linear DNA tem-
plate for a mir-30-based artificial miRNA shuttle. These
AttB sites can then recombine with AttP sites located in
the GRIM destination vector, to produce a longer AttL
site, which is an AttB/AttP hybrid (BP recombination;
Figure 1B). During the conceptual stages of this method,
we modelled the GRIM.miRNA
off transcript in silico;
based on its sequence and structure, we hypothesized
that the AttL site could interfere with miRNA produc-
tion because of steric hindrance and/or premature tran-
scriptional termination. Specifically, the AttL sequence
was predicted to fold into multiple hairpin secondary
structures (Figure 1B) that could inhibit transcriptional
read-through to the miRNA, and/or impair miRNA pro-
cessing (steric hindrance); and the AttL DNA template
contained three stretches of termination signals for pol
III-dependent transcripts (4 or more T’s; Figure 1B and
Additional File 5), which could prevent transcription of
the full-length primary miRNA transcript (premature
termination). From these concerns arose the strategy to
FLOX the AttL site and remove it with Cre recombi-
n a s e .A l t h o u g hw ep r e d i c t e dt h eA t t Ls i t ew o u l dp a r -
tially interfere with miRNA expression, we were
surprised to discover that its presence prevented
miRNA production altogether (Figures 1, 2). As a result,
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what unexpected, feature of the GRIM system. Never-
theless, the GRIM system is versatile, and Cre-
inducibility is optional. As previously mentioned, our
primary intention was to accelerate the miRNA shuttle
construction process, and our initial strategy involved
removing the inhibitory AttL site by simple transforma-
tion of GRIM.miRNA
off plasmids into Cre-expressing,
EL350 E. coli. This virtually foolproof step produces a
GRIM.miRNA
on plasmid that is then constitutively ‘on’
when delivered to mammalian cells.
We also built in a mechanism to excise the GRIM.
miRNA
on cassette and turn it ‘off’ permanently with Flp
recombinase, and tested the functionality of this off-
switch in stable cell lines (Figure 3). Our goal here was
to demonstrate that Flp recombinase could negatively
regulate our system. Indeed, transient Flp expression
significantly reversed GRIM.miLacZ-mediated silencing,
but we noted that bgal activity did not return to base-
line (Figure 3). This was likely because the heat-labile
CMV.Flp construct we used (pOG44, Stratagene) has
low activity at 37°C [56], which was the growth tem-
perature of our HEK293 stables. Indeed, the optimal
temperature for pOG44-derived Flp is 30°C. Exposing
GRIM.miLacZ
on stable HEK293 cells to heat-labile Flp
for a longer period of time, or expressing a thermostable
form of the protein, would further improve the effi-
ciency of gene silencing reversal.
Finally, the current GRIM vector described here relies
on the RNA pol III-dependent U6 promoter to drive
miRNA shuttle transcription. However, our strategy is
likely not limited to pol III promoters alone. Indeed,
inserting pol II poly A signals (AATAAA) in two different
locations within the current GRIM system would enable
the use of tissue-specific pol II promoters (Additional File
5). First, the pol III termination signal (TTTTTT) placed
at the 3’ end of the artificial miRNA can be replaced by
one or more minimal pol II poly A signals (AATAAA).
Second, if the putative pol III termination signals in the
AttL site inhibit miRNA production via premature termi-
nation of the primary transcript, an analogous situation
can be produced for a pol II promoter-driven transcript by
simply placing one or more AATAAA signals in the
GRIM destination vector just downstream of the first
LoxP site (Additional File 5). Cre excision would then de-
repress the pol II-dependent GRIM vector, allowing pro-
cessive miRNA transcription until correct termination at
the downstream polyA signal. As with the pol III-based
system described in this manuscript, the option to build in
the Flp/FRT shutdown mechanism would also provide the
vector with additional versatility. Thus, although the func-
tionality of such a system remains to be tested, building
tissue-specific pol II promoters into the GRIM system
could further expand the utility of this technology.
Conclusions
We developed a simple, rapid, and versatile system to gen-
erate miRNA expression plasmids using site-specific
recombinases. One of the major advantages of our strategy
is ease of construction; this feature has benefits for labs
with extensive or minimal molecular biology skills (Addi-
tional File 6). In addition, our method has a built-in Cre
recombinase-dependent ‘on’ switch that permits tight con-
trol of expression, and an optional mechanism to turn
expression ‘off’ using Flp recombinase. Our system can
therefore be used for more traditional gene silencing
experiments, but also has applications for making induci-
ble transgenic animals or RNAi therapeutics [44,57-60].
Additional material
Additional file 1: Detailed strategy for designing artificial GRIM
miRNAs and the primers required for their construction. Step1. This
strategy can be used to express a natural miRNA. However, in this
protocol, we describe engineering artificial GRIM miRNAs for knocking
down any gene of interest. Each GRIM miRNA is based on hsa-miR-30a
sequences and structure. The natural mir-30a mature sequences are
replaced by unique sense (blue text) and antisense (red text) sequences
derived from the target gene. In this example, we show the miLacZ and
miGFP constructs used in this manuscript. The orange nucleotides are
derived from human miR-30a, except the 3’ terminal poly U, which is
added for use as a termination signal for the pol III-dependent U6
promoter. The natural mir-30 Drosha and Dicer cut sites are maintained
and indicated by blue and yellow arrowheads, respectively. The
mismatch located just upstream of the Drosha cut site (at position -2)
should be maintained for proper processing. Choosing effective artificial
miRNA sequences targeting a gene of interest still requires some trial-
and-error empirical testing. However, there are several publications
describing specific rules for optimal inhibitory RNA design. We found
that incorporating two such guidelines improves the chances of
identifying effective artificial miRNA sequences. First, cellular gene
silencing proteins (RISC, RNA induced silencing complex) preferentially
load the more thermodynamically unstable 5’ end of a miRNA duplex (i.
e. more AU-rich). Thus, to ensure proper loading of the antisense guide
strand, the antisense miRNA strand should have more GC base pairs at
its 3’ end than its 5’ end (i.e. the last 3-4 bases on either side; see LacZ
and GFP target sites as an example of this requirement). Second, the
mature miRNA sequence should have 60% or less GC content. To
simplify design, we built both “rules” into our GRIM.REAPER miRNA
design program (Additional File 4). Step 2. The GRIM.miRNA is ultimately
transcribed from a DNA template. Step 2 illustrates the specific primer
extension strategy used to create the DNA template for a GRIM.miRNA.
Four primers are annealed and extended using a thermostable DNA
polymerase, such as Taq or Pfx. Commons Primers 1 and 2 are used for
all GRIM.miRNA constructions. Two unique primers with some common
features are used to generate each specific miRNA, as shown in the
miLacZ and miGFP examples here. Although the design strategy
provided here permits the end-user to create miRNAs and primer
sequences manually, we have automated this process using the GRIM.
REAPER design program (Additional File 4).
Additional file 2: Generating GRIM.miRNA vectors and screening for
positive clones. Step 3. Producing the DNA template for a Gateway
Ready miRNA by thermocycling 4 DNA oligos. One microgram each of
Common primers 1 and 2, and unique miRNA primers 1 and 2
(generated by the GRIM.REAPER design program), were annealed and
extended in a 50 microliter Pfx polymerase reaction (Invitrogen) as
follows: 95°C × 30 sec, 45°× 30 sec, and 68°C × 30 sec for 35 cycles. The
full-length 219 bp miRNA donor DNA was visualized on an ethidium
bromide stained agarose gel. BP recombination of this product does not
require gel or column purification. Step 4: BP Reaction. As described in
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cassette in the GRIM destination vector. This permits propagation in
ccdB-sensitive E. coli (i.e. most competent cell strains like DH5a or
TOP10). Positive colonies are also kanamycin resistant. Correctly
recombined GRIM.miRNA
off plasmids have two EcoRI bands of 900 bp
and 3,501 bp, as shown. In our hands, 90% of ccdB negative/kanamycin
resistant colonies showed the correct EcoRI restriction pattern. Step 5:
DNA sequencing. Plasmids showing the correct EcoRI restriction pattern
are DNA sequenced using an oligonucleotide primer located at the 3’
end of the U6 promoter (5’ CACAAAAGGAAACTCACCC 3’).
Additional file 3: Regulating the GRIM system with Cre or Flp. Step
6. The GRIM.miRNA
off vector is turned ‘on’ by Cre recombinase excision
of the inhibitory AttL1 site. To make a constitutively active vector, AttL1
excision can be accomplished through transformation of the GRIM.
miRNA
off vector into EL350 E. Coli, which express Cre recombinase. This
100% efficient reaction removes 175 bp from the plasmid, such that
EcoRI digestion yields 725 bp and 3,501 bp bands, as shown.
Alternatively, GRIM.miRNA
off vectors can be inducibly turned ‘on’ in
animal cells or tissues expressing Cre recombinase from tissue- or
temporal-specific promoters. Step 7. The GRIM.miRNA
on vector can be
turned ‘off’ with Flp recombinase, as described in the Methods.
Additional file 4: GRIM.REAPER miRNA design program. Using the
criteria described in Additional File 1, this Java-based software package
predicts highly functional artificial miRNAs from gene sequences entered
by the end-user. In addition, it outputs the sequence of the DNA
oligonucleotides required to build each GRIM.miRNA construct.
Instructions: (1) Paste the DNA sequence of the gene of interest into the
GRIM.REAPER query box. (2) Save the output text file locally. (3) Open the
file. Example output: Query sequence: 1073 nt
———————————————————— miRNA position: 70-91 Mature
Duplex: 5’ CGUUUGGACCCCGAGCCAAACU 3’
|||||||||||||||||||| 3’ GAGCAAACCUGGGGCUCGGUUU 5’
Full length GRIM.miRNA sequence: 5’UGUUGGACAGUGAG
CGAUCGUUUGGACCCCGAGCCAAACUGUAAAGCCACAGAUGGGUUUG
GCUCGGGGUCCAAACGAGCGCCUACUGUCACUUUUUU 3’ miRNA
primer 1: 5’ CCCATCTGTGGCTTTACAGTTTGGCTCGGGGTCCA
AACGATCGCTCACTGTCCAAC 3’ miRNA primer 2: 5’ CTGTAAAG
CCACAGATGGGTTTGGCTCGGGGTCCAAACGAGCGCCTACTGTCACTTT
3’.
Additional file 5: Model for converting the GRIM system from pol III
to pol II dependence. (A) We hypothesize that RNA pol III termination
signals (4-6 T’s) in the inhibitory AttL1 site cause premature termination
of GRIM.miRNAs, which prevents miRNA maturation and ultimately, gene
silencing. Cre removes the AttL1-resident poly T terminators, thereby
permitting full-length GRIM miRNA transcription and maturation. (B)
Based on this model, the current GRIM system could be used with a pol
II-based promoter as well, with some modifications. Specifically, the GRIM
destination vector can be modified to contain a pol II responsive poly A
signal downstream of the 5’ LoxP site, which would serve to prematurely
terminate a full-length GRIM.miRNA. A second poly A signal, downstream
of the miRNA cassette, can then be added during the miRNA donor
construction. In the unFLOXed state, the upstream poly A signal would
be utilized thereby preventing miRNA production and subsequent gene
silencing. Cre-mediated excision (FLOXed state) would remove the
upstream poly A signal along with the AttL1 site, thereby permitting full-
length miRNA transcription, maturation, and gene silencing.
Additional file 6: Flow chart comparing traditional cut-and-paste
molecular cloning methods versus the GRIM system. This chart
illustrates the streamlined cloning process afforded by the GRIM system,
compared to more traditional molecular construction methods. GRIM
cloning requires markedly less hands-on and overall time for miRNA
expression vector construction. Indeed, correct clones can be generated
and confirmed 1-2 days earlier than with traditional molecular methods.
Moreover, restriction enzyme and ligation-based methods can sometimes
be inefficient and vector generation may require repeated attempts. The
high cloning efficiency of the GRIM system (~90%) circumvents this
problem.
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